The Act on the Reform of the Market for Medicinal Products (AMNOG) has completely revised pricing regulations for newly authorized pharmaceuticals and their reimbursement by statutory health insurance (SHI) providers. Since 2011, findings from benefit evaluations of new medicines by the Federal Joint Committee (G-BA) form the basis for price negotiations between manufacturers and the SHI. The reimbursement price is defined as a rebate on the drug price at launch.

AMNOG Pricing Analysis

advisors in healthcare has developed a tool that overviews the outcomes of AMNOG price negotiations. The underlying dataset contains detailed information on all benefit assessments as well as final negotiated rebates to date. The basis for the evaluation of rebates are price information published by the official German drug price list “Lauertaxe”. If one new pharmaceutical was subject to more than one assessment, we considered the latest rebate update.

Rebates concerning Therapeutic Areas



For this part of the AMNOG pricing analysis, we calculated the average rebate per assessed therapeutic area. The results refer to product based evaluations and include both non-orphan and orphan drugs.

Rebates concerning Orphan Drugs vs. Non-Orphan Drugs



The following chart compares the average reimbursement rates for non-orphan and orphan drugs at a product level.

Correlation between Benefit Assessment and Rebates


This analysis part depicts a correlation between benefit assessments and reimbursement prices on a product basis. Benefit evaluations are conducted on a subpopulation level, which implies that different subpopulations of one product can be assigned to different benefit categories. In order to quantify an average product benefit, we weighted each of its assessed subpopulations with the respective number of patients. The results from separate analyses for non-orphan and orphan drugs are shown below.

You can request a download of the entire analysis free of charge.